The major development of the past decade in the first-line treatment of recurrent and/or
metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) was the …

Simple Summary Head and neck squamous cell carcinoma (HNSCC), in the locally
advanced setting, relapses in more than 50% of cases after surgery and/or chemo …

This review highlights the evidence-based data to support current best management
practices for patients with recurrent and/or metastatic (R/M) head and neck squamous cell …

The addition of cetuximab to platinum-based chemotherapy (cisplatin or carboplatin plus 5-
fluorouracil [5-FU]), followed by maintenance cetuximab until disease progression …

PURPOSE CheckMate 651 (ClinicalTrials. gov identifier: NCT02741570) evaluated first-line
nivolumab plus ipilimumab versus EXTREME (cetuximab plus cisplatin/carboplatin plus …

Introduction: The majority of patients with locally advanced head and neck squamous cell
carcinoma (HNSCC) will recur. The treatment of patients with recurrent/metastatic (R/M …

Background Cetuximab in combination with platinum and 5-fluorouracil is the standard of
care in the first-line treatment of patients with recurrent/metastatic head and neck squamous …

Abstract Background B490 (EudraCT# 2011-002564-24) is a randomized, phase 2b,
noninferiority study investigating the efficacy and safety of first-line cetuximab plus cisplatin …

Objective To assess the efficacy and safety of cetuximab in combination with cisplatin and 5-
fluorouracil for first-line treatment of Japanese patients with recurrent and/or metastatic …

Importance There remains an unmet need to improve clinical outcomes in patients with
recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) …